Is the Mediterranean Diet in Inflammatory Bowel Diseases Ready for Prime Time?
- PMID: 38314171
- PMCID: PMC10836973
- DOI: 10.1093/jcag/gwad041
Is the Mediterranean Diet in Inflammatory Bowel Diseases Ready for Prime Time?
Abstract
Background: The rising incidence of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), specifically in the developing world, suggests an important environmental effect. Amongst environmental influences, dietary factors, particularly the adoption of a westernized diet, have been specifically noticed. In contrast, the Mediterranean diet (MED), characterized by high intake of fruits, vegetables, whole grains, legumes, nuts, olive oil, and moderate consumption of animal and ultra processed foods, has shown potential positive effects in IBD.
Methods: Here we conducted a narrative review focusing on the evidence regarding the role of MED in IBD prevention and management.
Results: Epidemiological studies suggest inverse association of MED with CD development. Furthermore, adherence to MED has been associated with clinical improvement in active CD and maintenance of lower levels of inflammatory markers in UC, along with improved quality of life and lower mortality rates in IBD patients. Mechanistically, MED promotes a diverse and beneficial gut microbiota, possesses anti-inflammatory properties through polyphenols and dietary fats, and may modulate oxidative stress. In clinical practice, MED may be adapted to diverse disease phenotypes and cultural preferences, and is a sustainable, easy to maintain dietary approach.
Conclusion: Current evidence may support the integration of MED into clinical practice in IBD care. In future research, the efficacy of MED in specific IBD phenotypes should be assessed.
Keywords: Crohn’s disease; Mediterranean diet; inflammatory bowel disease; prevention; ulcerative colitis.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
Conflict of interest statement
L.G.: Janssen, Takeda, Abbvie, Pfizer, Galapagos, Ferring, Gutreat, Food industries organization, Altman, Tnuva. I.D.: Janssen, Abbvie, Altman research, Takeda, Pfizer, Genentech/Roche, Arena, Neopharm, Eli-Lilly, Gilead, Galapagos, Celltrion, Ferring, Falk Pharma, Cambridge Healthcare, Sublimity,Nestle, Wild bio, Gutreat, Food industries organization, Athos, Iterative Scopes, Celgene/BMS, Abbott.
Figures
References
-
- Alatab, Sudabeh, Sepanlou Sadaf G., Ikuta Kevin, Vahedi Homayoon, Bisignano Catherine, Safiri Saeid, Sadeghi Anahita, et al. . “The Global, Regional, and National Burden of Inflammatory Bowel Disease in 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017.” The Lancet Gastroenterology & Hepatology 5, no. 1 (2020): 17–30. 10.1016/s2468-1253(19)30333-4. - DOI - PMC - PubMed
-
- Agrawal, Manasi, Shah Shailja, Patel Anish, Pinotti Rachel, Colombel Jean Frederic, Burisch Johan.. “Changing Epidemiology of Immune-Mediated Inflammatory Diseases in Immigrants: A Systematic Review of Population-Based Studies.” Journal of Autoimmunity 105 (2019): 102303. 10.1016/j.jaut.2019.07.002. - DOI - PMC - PubMed
-
- Benchimol, Eric I, Mack David R., Guttmann Astrid, Nguyen Geoffrey C., To Teresa, Mojaverian Nassim, Quach Pauline, Manuel Douglas G... “Inflammatory Bowel Disease in Immigrants to Canada and Their Children: A Population-Based Cohort Study.” American Journal of Gastroenterology 110, no. 4 (2015): 553–63. 10.1038/ajg.2015.52. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources